Clinical Trial

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Name: ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies — clinical trial record (NCT06656494)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

Protocol Amendment History 1 change

notable Trial sites expanded: 15 -> 18 locations 2026-04-14

Trial Details

NCT Number	NCT06656494
Lead Sponsor	Beijing InnoCare Pharma Tech Co., Ltd.
Conditions	Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Enrollment	266 participants
Start Date	2024-12-18
Primary Completion	2027-06 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-13